Cognito Therapeutics, Inc. has secured $105.0 million in new investment capital from investors. This significant funding round will support the company's ongoing development of non-invasive neuromodulation therapies aimed at treating neurodegenerative diseases and enhancing human cognitive performance.
The company is recognized as a pioneer in its field, focusing on innovative approaches to conditions like Alzheimer’s disease. Cognito Therapeutics has completed multiple clinical studies, which have demonstrated the potential of its investigational therapeutic to safely slow or stop cognitive decline and the loss of brain volume in patients with Alzheimer’s. This progress led to the company receiving FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease, a recognition that underscores the potential impact of its technology. The company expects to commence pivotal studies in 2022, a critical step towards potential market availability. Its foundational technology originated from pioneering optogenetics research conducted by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.
This substantial capital infusion is crucial for Cognito Therapeutics as it prepares to advance its therapeutic platform through pivotal clinical trials. The company plans to strategically deploy the funds to accelerate its clinical development programs, scale its operational capabilities, and further expand its research and development initiatives. This investment underscores investor confidence in Cognito's technology and its potential to address significant unmet medical needs in neurodegenerative conditions.
The successful completion of this funding round positions Cognito Therapeutics to continue its trajectory of growth and innovation. With the secured capital, the company is well-resourced to pursue its mission of bringing its non-invasive treatment to patients globally, aiming to make a meaningful difference in the lives of individuals affected by neurodegenerative diseases.
